A 70-year-old ex-smoker with COPD on a short-acting beta-2 agonist reports increasing dyspnea. FEV1 is 45% of predicted. Which inhaled therapy is most...

Question

A 70-year-old ex-smoker with COPD on a short-acting beta-2 agonist reports increasing dyspnea. FEV1 is 45% of predicted. Which inhaled therapy is most appropriate to add next according to NICE?

Accepted Answer

Long-acting muscarinic antagonist (LAMA)

Answer

High-dose inhaled corticosteroid alone

Answer

LABA/ICS combination

Answer

Oral mucolytics

Answer

Intermittent IV antibiotics

ukmla MCQ (SBA): COPD

A 70-year-old ex-smoker with COPD on a short-acting beta-2 agonist reports increasing dyspnea. FEV1 is 45% of predicted. Which inhaled therapy is most appropriate to add next according to NICE?